Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's Disease

Brief Summary: Participants enrolled at the Alzheimer's Disease Research Center (ADRC) at Wake Forest School of Medicine will be invited to take part in this study. The purpose of this study is to identify and measure the amount of a protein called amyloid in the brain.It is thought that the build up of amyloid may be related to the development of Alzheimer's disease.

Detailed Description: Brain amyloid will be measured using PET with \[11C\]PiB. Participation will involve an initial brain scan and possibly a follow-up brain scan two years later.

The data collected in this study will help explain amyloid deposits in several groups of participants including adults with and without signs of memory impairment. The information collected will help find out who is more likely to have brain amyloid and when it increases the risk for developing memory problems. Research studies suggest that people with elevated levels of brain amyloid are at an increased risk for memory decline, but this does not mean that every person with amyloid build up will develop AD.

Recruitment & Eligibility

Inclusion Criteria

Exclusion Criteria

Primary Outcome Measures

Name	Time	Method
Amyloid deposition	2 years	Studying the initial amyloid deposition in participants as well as their rate of amyloid accumulation over time will help establish whether there is an early therapeutic window for intervention in high risk patients.

Secondary Outcome Measures

Name	Time	Method

Locations (1): Wake Forest Baptist Medical Center
🇺🇸
Winston-Salem, North Carolina, United States

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial